BCAL Diagnostics Ltd
BDX
Company Profile
Business description
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer that is safe, cost-effective, accurate, and available to all women regardless of age, race, and geographic location.
Contact
50 Clarence Street
Suite 506, Level 5
SydneyNSW2000
AUST: +61 290787671
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
stocks
Overpriced ASX listed consumer electronics retailers
Solid balance sheets, lower business risk and strong sales but investors are overly optimistic.
stocks
Nvidia and AMD: Maintain fair value estimate amid reports of Meta’s negotiations to buy Google TPUs
Our update on select stocks from the Semiconductors industry.
stocks
Alphabet: Gemini momentum and possible Meta TPU deal underscore AI capability
We think Alphabet is exceptionally well positioned in everything AI.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,898.90 | 10.20 | -0.11% |
| CAC 40 | 8,096.43 | 70.63 | 0.88% |
| DAX 40 | 23,726.22 | 261.59 | 1.11% |
| Dow JONES (US) | 47,427.12 | 1,181.71 | 2.56% |
| FTSE 100 | 9,691.58 | 82.05 | 0.85% |
| HKSE | 26,014.98 | 86.90 | 0.34% |
| NASDAQ | 23,214.69 | 189.10 | 0.82% |
| Nikkei 225 | 50,111.37 | 552.30 | 1.11% |
| NZX 50 Index | 13,432.20 | 129.81 | -0.96% |
| S&P 500 | 6,812.61 | 46.73 | 0.69% |
| S&P/ASX 200 | 8,604.60 | 10.30 | -0.12% |
| SSE Composite Index | 3,883.01 | 18.83 | 0.49% |